National Highway 152A (India)

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion

Retrieved on: 
Dienstag, Dezember 5, 2023
Other Manufacturing, Medical Devices, Medical Supplies, Chemicals, Plastics, Manufacturing, Other Health, Health, Pharmaceutical, General Health, Carbon, CDMO, Lung, DDL, Patient, Isocyanate, European, GWP, BMV, Pulmonary drug delivery, National Highway 152A (India), Partnership, Metered-dose inhaler, Drug delivery, Pharmaceutical industry, Engineered wood, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.
  • de C.V. (BMV: ORBIA*) Fluorinated Solutions business ( Koura ®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.
  • View the full release here: https://www.businesswire.com/news/home/20231205198764/en/
    This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice.
  • This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

Orbia's Koura Business opens world's first HFA 152a medical propellant production facility

Retrieved on: 
Donnerstag, März 31, 2022
Group, Climate change, United Kingdom, CARE, GWP, Patient, City, Adult, Polymer solution casting, Degenerative disease, Research, Environment, CCO, Precision agriculture, Health, National Highway 152A (India), Carbon, Quality of life, RARE, DPI, COPD, HFA, Netafim, AIR, Data communication, Solution, Asthma, Development, Merck Group, Chronic obstructive pulmonary disease, Food, B Corporation (certification), Respiration, Pharmaceutical industry, Renewable energy, Chiesi Farmaceutici, Chiesi Farmaceutici, Orbia

BOSTON, March 31, 2022 /PRNewswire/ -- Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies,[2] today opens a new HFA 152a production facility at their Runcorn site in the UK.

Key Points: 
  • BOSTON, March 31, 2022 /PRNewswire/ -- Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies,[2] today opens a new HFA 152a production facility at their Runcorn site in the UK.
  • [3]
    The opening of this new production facility was conducted by Alessandro Chiesi, CCO at Chiesi and Gregg Smith, President at Koura and marks a key milestone in delivering an environmentally-friendly medical propellant, HFA 152a, which has a low GWP (F-Gas AR4 124).
  • This new facility will see commercial-scale HFA 152a availability in the market by mid-2022, allowing pharmaceutical companies to meet 2025/2026 commercial product timeframes.
  • Gregg Smith, Koura President said: "This is a significant step forward in bringing our sustainable, greener medical propellant HFA 152a to the market.

Orbia's Koura Business opens world's first HFA 152a medical propellant production facility

Retrieved on: 
Donnerstag, März 31, 2022
Group, Climate change, United Kingdom, CARE, GWP, Multimedia, Patient, City, Adult, Polymer solution casting, Degenerative disease, Research, Environment, CCO, Precision agriculture, Health, National Highway 152A (India), Carbon, Quality of life, RARE, DPI, COPD, HFA, Netafim, AIR, Data communication, Solution, Asthma, Development, Merck Group, Chronic obstructive pulmonary disease, Food, B Corporation (certification), Respiration, Pharmaceutical industry, Renewable energy, Chiesi Farmaceutici, Chiesi Farmaceutici, Orbia

[3]

Key Points: 
  • [3]
    The opening of this new production facility was conducted by Alessandro Chiesi, CCO at Chiesi and Gregg Smith, President at Koura and marks a key milestone in delivering an environmentally-friendly medical propellant, HFA 152a, which has a low GWP (F-Gas AR4 124).
  • This new facility will see commercial-scale HFA 152a availability in the market by mid-2022, allowing pharmaceutical companies to meet 2025/2026 commercial product timeframes.
  • Gregg Smith, Koura President said: "This is a significant step forward in bringing our sustainable, greener medical propellant HFA 152a to the market.
  • Koura to supply medical propellant carbon footprint medical propellant to Chiesi Farmaceutici.